Franklin Resources Inc. boosted its position in shares of Collegium Pharmaceutical Inc by 98.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,797,902 shares of the specialty pharmaceutical company’s stock after buying an additional 890,868 shares during the period.
Category: RBC Financial Group
Puma Biotechnology Inc (PBYI) Rating Reiterated by Citigroup Inc.
‘s stock had its “buy” rating reissued by research analysts at Citigroup Inc. in a research report issued on Saturday. They currently have a $88.00 price target on the biopharmaceutical company’s stock.